eligibility_summary
Adults 18–75 with consent, ECOG 0–1, histologically confirmed B‑cell NHL expressing CD19/CD20, ≥1 evaluable lesion, and relapsed/refractory disease (primary refractory, R/R after ≥2 lines, or for LBCL/FL3B/t‑iNHL relapse ≤12 mo after first‑line CR or ≤12 mo post auto‑HSCT), life expectancy ≥3 mo, adequate labs. Exclude: inadequate washout, prior non‑CD19 autologous CAR‑T or autologous gene therapy, any allogeneic therapy/HSCT, HBV/HCV/HIV+, severe DMSO/drug allergy, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06295549 (Phase I, single-arm) in relapsed/refractory B‑cell non‑Hodgkin lymphoma. Intervention: LUCAR-G39P, an autologous dual-target CAR-T cell therapy. Mechanism: Patient T cells are engineered to express CARs that recognize CD19 and CD20 on malignant B cells, activating CAR signaling (CD3ζ with costimulation), cytokine release, and cytotoxic killing, dual targeting aims to reduce antigen escape seen with single-antigen CARs. Preconditioning: cyclophosphamide (alkylating agent) and fludarabine (purine analog) for lymphodepletion to enhance CAR-T expansion. Targets: CD19 and CD20 on B cells, engages T-cell effector pathways to eliminate B-cell tumors.